Serina Therapeutics, Inc. (SER): debt financing — AgeX draws remaining $1M under secured note; issues warrants for 756K shares

Serina Therapeutics, Inc.

Drew $1M from Juvenescence under Amended and Restated Secured Convertible Promissory Note dated Feb 9, 2023.
Repayment date for outstanding principal is February 14, 2024.
Issued warrants to purchase 756,429 shares of common stock at $0.661 per share.
Warrants issued in connection with the drawdown; exercise price based on March 30, 2023 closing price.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred convertible notes of $1 million with Juvenescence Limited maturing February 14, 2024.

Instrument: convertible notes
Principal: $1 million
Counterparty: Juvenescence Limited
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On April 4, 2023, AgeX drew the remaining $1 million of its credit available under the Amended and Restated Secured Convertible Promissory Note (“Secured Note”) dated February 9, 2023 with Juvenescence Limited (“Juvenescence”).

View on SEC.gov

89 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-011242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.